Asthma and COVID-19: a systematic review.
Allergy Asthma Clin Immunol
; 17(1): 5, 2021 Jan 06.
Article
en En
| MEDLINE
| ID: mdl-33407838
ABSTRACT
BACKGROUND:
Severe coronavirus disease-19 (COVID-19) presents with progressive dyspnea, which results from acute lung inflammatory edema leading to hypoxia. As with other infectious diseases that affect the respiratory tract, asthma has been cited as a potential risk factor for severe COVID-19. However, conflicting results have been published over the last few months and the putative association between these two diseases is still unproven.METHODS:
Here, we systematically reviewed all reports on COVID-19 published since its emergence in December 2019 to June 30, 2020, looking into the description of asthma as a premorbid condition, which could indicate its potential involvement in disease progression.RESULTS:
We found 372 articles describing the underlying diseases of 161,271 patients diagnosed with COVID-19. Asthma was reported as a premorbid condition in only 2623 patients accounting for 1.6% of all patients.CONCLUSIONS:
As the global prevalence of asthma is 4.4%, we conclude that either asthma is not a premorbid condition that contributes to the development of COVID-19 or clinicians and researchers are not accurately describing the premorbidities in COVID-19 patients.
Texto completo:
1
Banco de datos:
MEDLINE
Tipo de estudio:
Risk_factors_studies
/
Systematic_reviews
Idioma:
En
Año:
2021
Tipo del documento:
Article